CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 13 enrolled
Drug / intervention
Pegcetacoplandrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02461771
NCT02461771Phase 1Completed
CompareCT.gov

Assessment of Safety, Tolerability and Pharmacokinetics of Intravitreal APL-2 Therapy for Neovascular Age-Related Macular Degeneration (AMD)

Apellis Pharmaceuticals, Inc.·interventional·Posted Jun 3, 2015·Updated Oct 6, 2020

In Brief

A Phase 1 clinical trial evaluating Pegcetacoplan for Neovascular Age-Related Macular Degeneration. Completed, enrolled 13 participants across 4 sites in 2 countries.

Detailed Summary

The objective of this study is to provide initial safety, tolerability and pharmacokinetics information of intravitreal administration of pegcetacoplan in order to support further development into larger Phase II studies for treatment of patients with AMD.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNeovascular Age-Related Macular Degeneration
CountriesAustralia, United States
Collaborators--

Timeline

Phase 1CompletedFinished
201520162017201820192020202120222023202420252026
First PostedJun 3, 2015
Enrollment StartJan 28, 2015
Primary CompletionMar 8, 2016
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 11.1 years ago

Interventions

Pegcetacoplandrug

On treatment day, subjects will be administered a single 100 μL IVT injection of pegcetacoplan at the dose corresponding to their treatment assignment.